Several other equities research analysts also recently weighed in on ENDP. Cantor Fitzgerald set a $9.00 price target on Endo International and gave the stock a hold rating in a report on Monday, October 30th. Royal Bank of Canada reduced their price target on Endo International from $9.00 to $8.00 and set a sector perform rating on the stock in a report on Friday, November 10th. Citigroup reduced their price target on Endo International from $9.00 to $7.00 and set a neutral rating on the stock in a report on Friday, November 10th. BMO Capital Markets reduced their price target on Endo International from $11.00 to $10.00 and set a market perform rating on the stock in a report on Friday, November 10th. Finally, Mizuho reiterated a buy rating on shares of Endo International in a report on Friday, November 10th. Three investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Hold and a consensus price target of $10.32.
Shares of Endo International (ENDP) opened at $6.84 on Monday. The company has a quick ratio of 0.86, a current ratio of 1.08 and a debt-to-equity ratio of 10.78. Endo International has a fifty-two week low of $5.77 and a fifty-two week high of $14.45. The firm has a market capitalization of $1,531.93, a P/E ratio of -0.30, a PEG ratio of 2.40 and a beta of 0.29.
ILLEGAL ACTIVITY NOTICE: “Endo International (ENDP) Rating Lowered to Market Perform at JMP Securities” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3225301/endo-international-endp-rating-lowered-to-market-perform-at-jmp-securities.html.
Endo International Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.